Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
Venetoclax is a treatment for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, the pharmacokinetic data in Chinese population, as well as the change of venetoclax plasma concentration while taking CYP enzyme inducers or inhibitors, remained unknown so far. Therefore, the aim of this study is to investigate the pharmacokinetic characteristics of venetoclax.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: f
View:
• Adult patients (≥ 20 year-old) with diagnosis of chronic lymphocytic leukemia
• Patients who meet the above criteria and have already initiated or are going to receive venetoclax treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from July 2020 to December 2025
Locations
Other Locations
Taiwan
National Taiwan University Hospital
RECRUITING
Taipei
Contact Information
Primary
Shu-Wen Lin, Pharm.D
shuwenlin@ntu.edu.tw
886-2-33668782
Time Frame
Start Date: 2020-07-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 500
Treatments
Venetoclax
Adult CLL patients (≥ 20 year-old) who have already initiated or are going to receive venetoclax treatment at National Taiwan University Hospital/National Taiwan University Cancer Center from July 2020 to December 2025.
Related Therapeutic Areas
Sponsors
Leads: National Taiwan University Hospital